Tag Archives: Cancer

Patients on the Picket Line

Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
Posted in Biotech, FDA, healthcare, Legal, Market Access, Regulatory, Safety | Also tagged , , , , , , , , , , , | Leave a comment

Is There a Global Policy Gap on Cancer?

Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day.  Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the […]
Posted in Global | Also tagged , , | Leave a comment

Future Boom in Chronic Cancer Patients Likely to Change the Face of Disease, suggest ASCO Findings

Patients who live for many years following a cancer diagnosis will likely require additional support, and a whole new kind of follow-up care. by John Otrompke Dramatic developments in studies of patients with advanced cancer suggest that the day may be coming within our lifetime when most cancer patients will experience the disease as a […]
Posted in Strategy | Also tagged , | 1 Comment

First Orphan Launch a Challenge for AstraZeneca

Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names. Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, […]
Posted in FDA, Marketing, patient education, Safety, Strategy | Also tagged , , , , | Leave a comment

Cancer Testing Times: One Thing the UK Will Not Be Cutting

Buried among the savage, £83 billion-worth of cuts announced by the UK coalition government’s controversial Comprehensive Spending Review last week was confirmation that the Department of Health would not be taking forward the previous government’s pledge to introduce a one-week target for cancer testing. Under the Labour government, the time that it took for a […]
Posted in Europe, Global, Guest Blog | Also tagged , , , | Leave a comment
  • Categories

  • Meta